Long-term IGF-I treatment of children with Laron syndrome increases adiposity.
Laron syndrome (LS) is an autosomal recessive disease caused by deletions or mutations in the GH receptor gene leading to an inability of insulin-like growth factor I (IGF-I) generation. Among the major resulting body changes are dwarfism and obesity. The only effective treatment is daily administration of biosynthetic IGF-I. Body composition determination by DEXA (dual energy X-ray absorptiometry) of three girls with LS treated by IGF-I for 1, 3 and 11 1/2 years, respectively, revealed that concomitantly with the increase in growth there was a significant increase in body adipose tissue to double or triple the normal values. Due to the underdevelopment of the muscular and skeletal systems body mass index (BMI) did not accurately reflect the degree of obesity. In conclusion, IGF-I similar to insulin, exerts an adipogenic effect.
Laron
Zvi
Z
Endocrinology and Diabetes Research Unit, Schneider Children's Medical Center, 14 Kaplan Street, 49202 Petah Tikva, Israel. laronz@clalit.org.il
Ginsberg
Shira
S
Lilos
Pnina
P
Arbiv
Mira
M
Vaisman
Nahum
N
D050154:Adiposity / Q000187:drug effects*; D002648:Child; D002675:Child, Preschool; D005260:Female; D006801:Humans; D007334:Insulin-Like Growth Factor I / Q000494:pharmacology / Q000627:therapeutic use*; D046150:Laron Syndrome / Q000188:drug therapy / Q000378:metabolism*
D007334:Insulin-Like Growth Factor I